CA2489298A1 - Novel antagonists of cxcr3-binding cxc chemokines - Google Patents

Novel antagonists of cxcr3-binding cxc chemokines Download PDF

Info

Publication number
CA2489298A1
CA2489298A1 CA002489298A CA2489298A CA2489298A1 CA 2489298 A1 CA2489298 A1 CA 2489298A1 CA 002489298 A CA002489298 A CA 002489298A CA 2489298 A CA2489298 A CA 2489298A CA 2489298 A1 CA2489298 A1 CA 2489298A1
Authority
CA
Canada
Prior art keywords
antagonists
cxcr3
cxcl11
sequence
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002489298A
Other languages
French (fr)
Other versions
CA2489298C (en
Inventor
Amanda Proudfoot
Marie Kosco-Vilbois
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Applied Research Systems Ars Holding N.V.
Amanda Proudfoot
Marie Kosco-Vilbois
Laboratoires Serono S.A.
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V., Amanda Proudfoot, Marie Kosco-Vilbois, Laboratoires Serono S.A., Merck Serono Sa filed Critical Applied Research Systems Ars Holding N.V.
Publication of CA2489298A1 publication Critical patent/CA2489298A1/en
Application granted granted Critical
Publication of CA2489298C publication Critical patent/CA2489298C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Novel antagonists of CXCR3 -binding CXC chemokines, and in particular of hum an CXCL11, can be obtained by generating mutants of such chemokines in which th e binding to glycosaminoglycans (GAGs) is impaired due to non-conservative substitutions of amino acids involved in this interaction. Compounds prepare d in accordance with the present invention can be used to block the activity o f CXCR3-binding CXC chemokines on CXCR3 -expressing cells, thereby providing therapeutic compositions for use in the treatment or prevention of diseases related to excessive activated T cells migration, such as graft rejection an d autoimmune diseases, and of diseases needing an increase of vascularization, such as ischemic heart disease.

Claims (36)

1. Antagonists of CXCR3-binding CXC chemokines consisting of mutants of CXCL11, CXCL10, or CXCL9 in which at least one of the following basic residues, numbered on the sequence of human mature CXCL11, is substituted to Alanine, Glycine, Serine, Threonine, Proline, Glutammic Acid, Glutamine, Aspartic Acid, or Asparagine: 46, 62, 66, and 70.
2. The antagonists of claim 1 wherein CXCR3-binding CXC chemokine is human CXCL11 and at least one of the following basic residues, numbered on the sequence of human mature CXCL11, is additionally substituted to Alanine, Glycine, Serine, Threonine, Proline, Glutammic Acid, Glutamine, Aspartic Acid, or Asparagine: 49, 52, 57, 59, 67, or 71.
3. The antagonists of claim 2 wherein one of the following combinations of basic residues, numbered on the sequence of human mature CXC L11, is substituted to Alanine, Glycine, Serine, Threonine, Proline, Glutammic Acid, Glutamine, Aspartic Acid, or Asparagine:
a) 46, together with 49 and/or 52;
b) 62, together with 57 and/or 59;
c) 66 and 70, together with 67 and/ or 71; or d) 62 and 66, together with one or more of the following: 57, 59, 67, 70, or 71.
4. The antagonists of claim 2 or 3 wherein at least one of the following basic residues, numbered on the sequence of human mature CXCL11, is additionally substituted to Alanine, Glycine, Serine, Threonine, Proline, Glutammic Acid, Glutamine, Aspartic Acid, or Asparagine: 5, 6, 8, 17, 20, 26 or 38.
5. The antagonists of claim 1 wherein CXCR3-binding CXC chemokine is human CXCL10 and at least one of the following basic residues, numbered on the sequence of human mature CXCL11, is additionally substituted to Alanine, Glycine, Serine, Threonine, Proline, Glutammic Acid, Glutamine, Aspartic Acid, or Asparagine: 47, 48, 51, 52, 59, 74, or 75.
6. The antagonists of claim 5 wherein one of the following combinations of basic residues, numbered on the sequence of human mature CXCL11, is substituted to Alanine, Glycine, Serine, Threonine, Proline, Glutammic Acid, Glutamine, Aspartic Acid, or Asparagine:
a) 46 and 52, together with 47, 48, or 51;
b) 59 and 62;
c) 66 and 70, together with 74 and/or 75; or d) 62 and 66, together with 59 and/or 70.
7. The antagonists of claim 5 or 6 wherein at least one of the following basic residues, numbered on the sequence of human mature CXCL11, is additionally substituted to Alanine, Glycine, Serine, Threonine, Proline, Glutammic Acid, Glutamine, Aspartic Acid, or Asparagine: 5, 8, 22, 26 , or 38.
8. The antagonists of claim 1 wherein CXCR3-binding CXC chemokines is human CXCL9 and basic residue 67, numbered on the sequence of human mature CXCL11, is additionally substituted to Alanine, Glycine, Serine, Threonine, Proline, Glutammic Acid, Glutamine, Aspartic Acid, or Asparagine.
9. The antagonists of claim 8 wherein one of the following combinations of basic residues, numbered on the sequence of human mature CXCL11, is substituted to Alanine, Glycine, Serine, Threonine, Proline, Glutammic Acid, Glutamine, Aspartic Acid, or Asparagine:
a) 62, together with 66 and/or 67;
b) 66 and 67; or c) 66 and 70, together with one or more of the following: 67, 74, or 75.
10. The antagonists of claim 8 or 9 wherein at least one of the following basic residues, numbered on the sequence of human mature CXCL11, is additionally substituted to Alanine, Glycine, Serine, Threonine, Proline, Glutammic Acid, Glutamine, Aspartic Acid, or Asparagine: 5, 6, 8, 25, 28 , or 38.
11. The antagonists of claims 1 to 10 wherein the basic residues are substituted with Alanine or Glycine.
12. The antagonists of claim 11 having the sequence of CXCL11-2B3 (SEQ ID NO:
3), CXCL11-3B3 (SEQ ID NO: 4), or CXCL11-4B4 (SEQ ID NO: 5).
13. The antagonists of claims 1 to 12 wherein one or more amino acids that have been added, deleted, or substituted belong to the first nine amino acids in the amino-terminal domain of the human mature CXCR3-binding CXC chemokine.
14. The antagonists of claims 1 to 13 wherein one or more amino acids have been mutated to decrease the aggregation properties of said antagonist.
15. Antagonists of CXCR3-binding CXC chemokines comprising the antagonists of claims 1 to 14, and an amino acid sequence belonging to a protein sequence other than the corresponding CXCR3-binding CXC chemokine.
16. The antagonists of claim 15, comprising an amino acid sequence belonging to one or more of these protein sequences: extracellular domains of membrane -bound protein, immunoglobulin constant region, multimerization domains, extracellular proteins, signal peptide-containing proteins, export signal-containing proteins.
17. Antagonists of CXCR3-binding CXC chemokines comprising peptide mimetics designed on the sequence and/or the structure of the antagonists of claims 1 to 14.
18. Active fractions, precursors, salts, or derivatives of the antagonists of binding CXC chemokines of claims 1 to 17.
19. The antagonists of claims 1 to 18, wherein said antagonist is in the form of active conjugate or complex with a molecule chosen amongst radioactive labels, biotin, fluorescent labels, cytotoxic agents, or drug delivery agents.
20. DNA molecules comprising the DNA sequences coding for the antagonists of claims from 1 to 16, including nucleotide sequences substantially the same.
21. Expression vectors comprising the DNA molecules of claim 20.
22. A host cell transformed with a vector of claim 21.
23. Use of the antagonists of claims from 1 to 19, of the DNA of claims 20 or 21, or of the cells of claim 22, as active ingredients in pharmaceutical compositions for the treatment or prevention of diseases related to excessive leukocyte migration and activation.
24. The use of claim 23 wherein the disease is an inflammatory disease, an autoimmune disease or an infection.
25. The use of claim 24 wherein the disease is multiple sclerosis, rheumatoid arthritis, HIV-1 infection, type I diabetes, or graft rejection.
26. Use of the antagonists of claims from 1 to 19, of the DNA of claims 20 or 21, or of the cells of claim 22, as active ingredients in pharmaceutical compositions for the treatment or prevention of diseases needing an increase of vascularization.
27. The use of claim 26 wherein the disease is an ischemic heart disease.
28. Use of the antagonists of claims from 1 to 19, of the DNA of claims 20 or 21, or of the cells of claim 22, as active ingredients in pharmaceutical compositions for the treatment or prevention of cancer.
29. Process of preparation of antagonists of claims from 1 to 14, comprising culturing the transformed cells of claim 17 and collecting the expressed proteins.
30. Pharmaceutical composition containing an antagonist of CXCR3-binding CXC
chemokines of claims from 1 to 19, the DNA of claims 20 or 21, or the cells of claim 22, as active ingredient.
31. Process for the preparation of pharmaceutical compositions for the treatment or prevention of diseases related to excessive leukocyte migration and activation, which comprises combining an antagonist of CXCR3-binding CXC chemokines of claims from 1 to 19, the DNA of claims 20 or 21, or the cells of claim 22, together with a pharmaceutically acceptable carrier.
32. Process for the preparation of pharmaceutical compositions for the treatment or prevention of diseases needing an increase of vascularization, which comprises combining an antagonist of CXCR3-binding CXC chemokines of claims from 1 to 19, the DNA of claims 20 or 21, or the cells of claim 22, together with a pharmaceutically acceptable carrier.
33. Process for the preparation of pharmaceutical compositions for the treatment or prevention of cancer, which comprises combining an antagonist of CXCR3-binding CXC chemokines of claims from 1 to 19, the DNA of claims 20 or 21, or the cells of claim 22, together with a pharmaceutically acceptable carrier.
34. Method for the treatment or prevention of diseases related to excessive leukocyte migration and activation, comprising the administration of an effective amount of an antagonist of CXCR3-binding CXC chemokines of claims from 1 to 19, of the DNA of claims 20 or 21, or of the cells of claim 22.
35. Method for the treatment or prevention of diseases needing an increase of vascularization, comprising the administration of an effective amount of an antagonist of CXCR3-binding CXC chemokines of claims from 1 to 19 of the DNA
of claims 20 or 21, or of the cells of claim 22.
36. Method for the treatment or prevention of cancer, comprising the administration of an effective amount of an antagonist of CXCR3-binding CXC chemokines of claims from 1 to 19, of the DNA of claims 20 or 21, or of the cells of claim 22.
CA2489298A 2002-06-12 2003-06-03 Novel antagonists of cxcr3-binding cxc chemokines Expired - Fee Related CA2489298C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02100697 2002-06-12
EP02100697.8 2002-06-12
PCT/EP2003/050211 WO2003106488A2 (en) 2002-06-12 2003-06-03 Novel antagonists of cxcr3-binding cxc chemokines

Publications (2)

Publication Number Publication Date
CA2489298A1 true CA2489298A1 (en) 2003-12-24
CA2489298C CA2489298C (en) 2012-09-11

Family

ID=29724537

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2489298A Expired - Fee Related CA2489298C (en) 2002-06-12 2003-06-03 Novel antagonists of cxcr3-binding cxc chemokines

Country Status (16)

Country Link
US (1) US7541435B2 (en)
EP (1) EP1515990B1 (en)
JP (1) JP4394569B2 (en)
AR (1) AR040200A1 (en)
AT (1) ATE359297T1 (en)
AU (1) AU2003255505B2 (en)
CA (1) CA2489298C (en)
CY (1) CY1106799T1 (en)
DE (1) DE60313168T2 (en)
DK (1) DK1515990T3 (en)
ES (1) ES2282666T3 (en)
IL (1) IL165727A (en)
NO (1) NO332309B1 (en)
PT (1) PT1515990E (en)
SI (1) SI1515990T1 (en)
WO (1) WO2003106488A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045525A2 (en) * 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
WO2005084708A1 (en) * 2004-03-09 2005-09-15 Kyoto University Medicinal composition containing cxcr3 inhibitor
ITFI20040243A1 (en) * 2004-11-25 2005-02-25 Paola Romagnani DIAGNOSTIC METHOD FOR REJECTION OF TRANSPLANTED ORGAN
WO2006069449A1 (en) * 2004-12-29 2006-07-06 The University Of British Columbia Chemokine receptor-independent immunomodulatory and anti-proliferative activity
JP2008545396A (en) * 2005-05-18 2008-12-18 インターミューン インコーポレイテッド Non-natural chemokine receptor ligands and methods of use thereof
US8367052B2 (en) 2007-03-26 2013-02-05 General Regeneratives Holdings Inc. Methods for promoting protection and regeneration of bone marrow using CXCL9 and anti-CXCL9 antibodies
WO2008149354A2 (en) * 2007-06-04 2008-12-11 Rappaport Family Institute For Research In The Medical Sciences Agents for the treatment of inflammatory diseases and methods of using same
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
US10983128B2 (en) 2015-02-05 2021-04-20 Bristol-Myers Squibb Company CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
WO2016176583A1 (en) * 2015-04-29 2016-11-03 Sanford-Burnham Medical Research Institute Modulation of immune response using btla agonist antibodies
EP3551047A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
US10980739B2 (en) 2016-12-14 2021-04-20 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
US20230023414A1 (en) 2018-11-19 2023-01-26 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
US5656724A (en) * 1994-10-26 1997-08-12 Repligen Corporation Chemokine-like proteins and methods of use
US5707829A (en) * 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
US6140064A (en) * 1996-09-10 2000-10-31 Theodor-Kocher Institute Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3
US5977334A (en) * 1997-09-11 1999-11-02 The Cleveland Clinic Foundation DNA encoding a chemokine, Beta R1, comprising the Beta R1 promoter
AU2001253496A1 (en) * 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Treating graft rejection with cxcr3 inhibitors
EP1307216A4 (en) * 2000-07-12 2005-01-12 Gryphon Therapeutics Inc Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use
MXPA03004913A (en) 2000-12-01 2003-09-05 Schering Corp Uses of mammalian genes and related reagents.

Also Published As

Publication number Publication date
NO332309B1 (en) 2012-08-20
IL165727A0 (en) 2006-01-15
DE60313168D1 (en) 2007-05-24
AU2003255505B2 (en) 2009-01-08
NO20050162L (en) 2005-01-12
WO2003106488A2 (en) 2003-12-24
DE60313168T2 (en) 2007-12-20
CY1106799T1 (en) 2012-10-24
WO2003106488A3 (en) 2004-04-15
AU2003255505A1 (en) 2003-12-31
SI1515990T1 (en) 2007-08-31
IL165727A (en) 2010-05-17
ES2282666T3 (en) 2007-10-16
PT1515990E (en) 2007-05-31
EP1515990A2 (en) 2005-03-23
DK1515990T3 (en) 2007-06-11
JP2006511200A (en) 2006-04-06
EP1515990B1 (en) 2007-04-11
CA2489298C (en) 2012-09-11
JP4394569B2 (en) 2010-01-06
ATE359297T1 (en) 2007-05-15
US7541435B2 (en) 2009-06-02
US20060204498A1 (en) 2006-09-14
AR040200A1 (en) 2005-03-16

Similar Documents

Publication Publication Date Title
EP1286684B1 (en) use of cxcr4 antagonists for treating autoimmune diseases and cancer
CA2489298A1 (en) Novel antagonists of cxcr3-binding cxc chemokines
US20090192082A1 (en) Cxcr4 antagonist treatment of hematopoietic cells
US9567371B2 (en) Short beta-defensin-derived peptides
US20080193426A1 (en) Migration of hematopoietic stem cells and progenitor cells to the liver
Li et al. Chemokines in cardiac fibrosis
CA2006964A1 (en) Human derived monocyte attracting purified protein product useful in a method of treating infection and neoplasms in a human body, and the cloning of full cdna thereof
US7553483B2 (en) Chemokine mutants acting as chemokine antagonists
PL204231B1 (en) Chemokine mutants in the treatment of multiple sclerosis
CN101016339A (en) Dual active protein containing stroma cell derivative factor-1 and immunoglobulin-Fc section, and application thereof
EP0519976A1 (en) Neutrophil stimulating peptides.
EP1673388B1 (en) Cxcl8 antagonists
KR20160132031A (en) Chemokine Receptor Antagonist and Its Combinational Therapy
BIKON Lymphokine-activated killer cells, natural killer cells and cytokines
CA2226391A1 (en) N-terminal peptides of sdf-1 have functional activities mediated by cxcr4
TW200808341A (en) Use of TPO peptide compounds and pharmaceutical compositions in the treatment of anemia

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140603